ArticleBiomolecules & biomedicine2025
Glioblastoma induces CAF-like astrocyte activation via the AKT/mTOR-SERPINH1/COL5A1 axis.
Article in Biomolecules & biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The Origin of Cancer-Associated Fibroblasts (CAFs) in Brain Metastases: Seven Hypotheses and Current Evidence.Cancers · 2026Review
- Precision Immunotherapeutics for Glioblastoma: Current Approaches and Emerging Strategies in 2026.Cells · 2026Review
- The Interaction of PI3K/AKT/mTOR Pathway with the Tumor Microenvironment: A Dual Engine Driving Breast Cancer Progression and Reshaping Treatment Strategies.Cancer management and research · 2026Review
- Pericyte-derived cancer-associated fibroblasts correlate with poor survival and are enriched after chemoradiotherapy in glioblastoma.PloS one · 2026Article
- Correction: Glioblastoma induces CAF-like astrocyte activation via the AKT/mTOR-SERPINH1/COL5A1 axis.Biomolecules & biomedicine · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma multiforme (GBM), the most aggressive form of glioma, remains the most malignant tumor of the central nervous system. Despite a range of therapeutic strategies, the prognosis for GBM patients remains poor, underscoring the urgent need for novel treatments to inhibit GBM progression. The tumor microenvironment (TME) plays a critical role in tumor development, with cancer-associated fibroblasts (CAFs) acting as key components. However, the origin, composition, and spatial distribution of CAFs within the GBM microenvironment remain poorly understood. To address this gap, our research aims to investigate the etiology, cellular composition, and precise localization of CAFs in GBM, with the goal of elucidating their role in oncogenesis and tumor progression, thereby providing new avenues for therapeutic intervention. In this study, we developed a novel CAF-related prognostic model using data from the TCGA and GEO databases and identified SERPINH1 and COL5A1 as CAF-related genes in GBM. We established a GBM mouse model as well as a GBM cell and astrocyte co-culture system to examine the expression of SERPINH1 and COL5A1 in astrocytes under a simulated tumor microenvironment. Our findings revealed that these genes were more highly expressed in peritumoral tissue compared to normal brain tissue and showed strong co-localization with astrocytes. Furthermore, we found that normal astrocytes can be induced by GBM cells to activate the AKT/mTOR signaling pathway, migrate to the peritumoral region, and upregulate CAF-associated proteins (SERPINH1/COL5A1). These results suggest that astrocytes may serve as a potential source of CAF precursor cells within the GBM tumor microenvironment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.